BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc., a biotechnology company that develops preventative and therapeutic technologies to reduce the morbidity and mortality caused by viral diseases, today announced the award of an approximately $300,000 Phase 1 Small Business Innovative Research (SBIR) grant from the Division of AIDS, National Institutes of Health. The focus of the grant is to develop enhanced adjuvants based on Profectus’ proprietary technology, in collaboration with the Institute of Human Virology at the University of Maryland. The grant will help support the development of one part of the company’s diverse genetic adjuvant portfolio of research.
